Optical Genome Mapping as a New Tool to Overcome Conventional Cytogenetics Limitations in Patients with Bone Marrow Failure
Genes · 2024
DOI: 10.3390/genes15050559 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2024. Verfasst von June Iriondo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Hemotherapy Unit, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain. Hauptthemen laut MEDLINE: In Situ Hybridization, Fluorescence. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, European Union, Carlos III Health Institute of the Ministry of Science.
Abstract (Originalsprache)
Cytogenetic studies are essential in the diagnosis and follow up of patients with bone marrow failure syndromes (BMFSs), but obtaining good quality results is often challenging due to hypocellularity. Optical Genome Mapping (OGM), a novel technology capable of detecting most types chromosomal structural variants (SVs) at high resolution, is being increasingly used in many settings, including hematologic malignancies. Herein, we compared conventional cytogenetic techniques to OGM in 20 patients with diverse BMFSs. Twenty metaphases for the karyotype were only obtained in three subjects (15%), and no SVs were found in any of the samples. One patient with culture failure showed a gain in chromosome 1q by fluorescence in situ hybridization, which was confirmed by OGM. In contrast, OGM provided good quality results in all subjects, and SVs were detected in 14 of them (70%), mostly corresponding to cryptic submicroscopic alterations not observed by standard techniques. Therefore, OGM emerges as a powerful tool that provides complete and evaluable results in hypocellular BMFSs, reducing multiple tests into a single assay and overcoming some of the main limitations of conventional techniques. Furthermore, in addition to confirming the abnormalities detected by conventional techniques, OGM found new alterations beyond their detection limits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology and Hemotherapy Unit, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain.
- Biomedical Research Foundation, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain.
- Laboratory and Clinical Analysis Department, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain.
- Pediatric Onco-Hematology Department, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain.
- Health Research Institute at Hospital de La Princesa (IIS-Princesa), 28006 Madrid, Spain.
ORCID-Profile: Josune Zubicaray, Jorge Garcia-Martinez, Elena Sebastián, Manuel Ramírez, Julián Sevilla
Förderung
- Instituto de Salud Carlos III
- European Union
- Carlos III Health Institute of the Ministry of Science
Zitieren
APA
Iriondo, J., Gómez, A., Zubicaray, J., Garcia-Martinez, J., Abad, L., Matesanz, C., Giménez, R., Galán, A., Sanz, A., Sebastián, E., González de Pablo, J., de la Cruz, A., Ramírez, M., & Sevilla, J. (2024). Optical Genome Mapping as a New Tool to Overcome Conventional Cytogenetics Limitations in Patients with Bone Marrow Failure. Genes. https://doi.org/10.3390/genes15050559
Vancouver
Iriondo J, Gómez A, Zubicaray J, Garcia-Martinez J, Abad L, Matesanz C, et al. Optical Genome Mapping as a New Tool to Overcome Conventional Cytogenetics Limitations in Patients with Bone Marrow Failure. Genes. 2024. doi:10.3390/genes15050559
BibTeX
@article{Iriondo2024,
author = {Iriondo, June and Gómez, Ana and Zubicaray, Josune and Garcia-Martinez, Jorge and Abad, Lorea and Matesanz, Carmen and Giménez, Reyes and Galán, Almudena and Sanz, Alejandro and Sebastián, Elena and González de Pablo, Jesús and de la Cruz, Ana and Ramírez, Manuel and Sevilla, Julián},
title = {Optical Genome Mapping as a New Tool to Overcome Conventional Cytogenetics Limitations in Patients with Bone Marrow Failure},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15050559}
}
EUVIMED